Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), announced a new organizational structure and related executive positions, designed to achieve seamless global integration, focus and effectiveness across the company. The changes will become effective July 1(st) . Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), net profit margin is 6.80% and weekly performance is 0.35%. On last trading day company shares ended up $51.95. Analysts mean target price for the company is $55.91. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), distance from 50-day simple moving average (SMA50) is 3.42%.
GlaxoSmithKline plc (ADR) (NYSE:GSK)‘s stock had its “buy” rating reaffirmed by equities research analysts at Societe Generale in a research note issued to investors on Wednesday. They currently have a GBX 2,050 ($34.51) price target on the stock. Societe Generale’s price target suggests a potential upside of 26.82% from the stock’s previous close. GlaxoSmithKline plc (ADR) (NYSE:GSK), fell 0.52% in last trading session and ended the day on $53.66. GSK, Gross Margin is 69.60% and its return on assets is 17.30%. GlaxoSmithKline plc (ADR) (NYSE:GSK), quarterly performance is -2.72%.
Newly reported data for AstraZeneca plc (ADR) (NYSE:AZN)’s experimental cancer treatments “gives credibility” to the drugmaker’s forecast of $45 billion in annual revenue by 2023, according to Chief Executive Officer Pascal Soriot. AstraZeneca plc (ADR) (NYSE:AZN), shares moved up 1.62% in last trading session and was closed at $73.37, while trading in range of $72.65 – 73.57. AstraZeneca plc (ADR) (NYSE:AZN), year to date (YTD) performance is 27.14%.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s stock declined 1.76% to $6.15. The company on May 12 reported financial results for the first quarter ended March 31, 2014. The company’s first quarter revenues totaled $6.8 million. Net loss was $25.3 million, or $0.12 per share. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), ended the last trading day at $6.06. Company weekly volatility is calculated as 3.44% and price to cash ratio as 5.19. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), showed a negative weekly performance of 2.10%.
On May 23, 2014, DAIICHI SANKYO CO LT (OTCMKTS:DSKYF), announced that it has received approval in Japan for partial modification to Ranmark (denosumab, genetic recombination (subcutaneous injection 120mg)), a gene recombinant drug to treat giant cell tumor of bone (GCTB). DAIICHI SANKYO CO LT (OTCMKTS:DSKYF), on last trading day company shares ended up $17.22.